Society for Endocrinology BES 2012

Programme

19 March 2012
09:00 11:00  REGISTRATION
11:00 13:00  Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S PITUITARY SPECIAL INTEREST GROUP AND THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
QUEEN'S SUITE A
Chairs: R Fowkes (London) & H Chahal (London)
11:00S1.1Genetic models of pituitary disease in MEN1
R Thakker (Oxford)
   
11:30S1.2Modelling pituitary tumours in zebrafish
N-A Liu (Los Angeles, CA, USA)
   
12:00S1.3Mouse model of craniopharyngioma
J Martinez-Barbera (London)
   
12:30S1.4Molecular signatures of pituitary tumours
M Korbonits (London)
   
11:00 13:00  Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Stress caused by unfolded and misfolded proteins in the endoplasmic reticulum (so called "ER stress") intersects with metabolic disease at multiple levels
QUEEN'S SUITE B
Chairs: P Chapple (London) & E Harno (Manchester)
11:00S2.1ER stress and metabolic regulation
D Ron (Cambridge)
   
11:30S2.2ER stress, leptin signalling and obesity
U Ozcan (Boston, MA, USA)
   
12:00S2.3Lipotoxic endoplasmic reticulum stress and pancreatic beta-cell demise in type 2 diabetes
M Cnop (Brussels, Belgium)
   
12:30S2.4Patients with monogenic diabetes resulting from ER stress of the pancreatic beta-cell
A Hattersley (Plymouth)
   
11:00 13:00  Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S ANDROLOGY SPECIAL INTEREST GROUP AND THE KLINEFELTER'S SYNDROME ASSOCIATION
MAIN AUDITORIUM
Chairs: R Quinton (Newcastle) & A Theodoraki (London)
11:00S3.1Is there a male menopause - lesson from the European Male Ageing Study
F Wu (Manchester)
   
11:30S3.2Does testosterone treatment increase mortality in elderly men?
S Bhasin (Boston, MA, USA)
   
12:00S3.3What is the best form of testosterone replacement?
P Bouloux (London)
   
12:30S3.4Can testosterone therapy be stopped in some hypogonadal patients?
T Raivio (Helsinki, Finland)
   
13:00 13:30  LUNCH
HALL Q
13:30 15:30  Applied Physiology Workshop:
NANOMEDICINE
QUEEN'S SUITE B
Chairs: M Gurnell (Cambridge) & R Fowkes (London)
13:30AP1.1Magnetic nanoparticles for drug delivery
P Southern (London)
   
14:10AP1.2Nanoparticles as imaging agents
G Lanza (St Louis, MO, USA)
   
14:50AP1.3Nanomedicine in clinical diabetes
J Pickup (London)
   
13:30 15:30  Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
QUEEN'S SUITE A
Chairs: G Karsenty (New York, NY, USA) & J Newell-Price (Sheffield)
13:30OC1.1Functional characterisation and translational clinical applications of kisspeptin-10
J George (Edinburgh)
   
13:45OC1.2Structure-function analysis of calcium-sensing receptor (CaSR) mutations reveal clustering at calcium binding sites of the extracellular bilobed venus flytrap domain
F Hannan (Oxford)
   
14:00OC1.3Effect of selenium status on the skeleton in post-menopausal women: the OPUS study
A Gogakos (London)
   
14:15OC1.4The thyroid hormone receptor-coactivator interface mediates negative feedback regulation of the human pituitary-thyroid axis
C Moran (Cambridge)
   
14:30OC1.5Growth retardation and severe constipation due to the first human, dominant negative thyroid hormone receptor alpha mutation
N Schoenmakers (Cambridge)
   
14:45OC1.6A homozygous glutathione peroxidase 1 mutation, p.Arg130-Leu133del, in a patient with familial glucocorticoid deficiency
J Kowalczyk (London)
   
15:00OC1.7Progressive adrenal insufficiency and 46,XY DSD caused by two novel mutations in the cytochrome P450 side-chain cleavage (CYP11A1) gene
S Parajes (Birmingham)
   
15:15OC1.8Metastasis related methyltransferase 1 (Merm1)/WBSCR22 regulates glucocorticoid receptor (GR) function
M Jangani (Manchester)
   
13:30 15:30  Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Thyroid cancer management is evolving to reflect novel developments in imaging, cytology, molecular biology and the outcome of trials evaluating low versus high dose radioiodine therapy
MAIN AUDITORIUM
Chairs: K Boelaert (Birmingham) & P Newey (Oxford)
13:30S4.1Can imaging predict malignancy in a thyroid nodule?
P Richards (London)
   
14:00S4.2Predictive value of cytology and molecular markers in thyroid cancer
T Stephenson (Sheffield)
   
14:30S4.3The place of radioiodine in the management of thyroid cancer
I Hay (Rochester, MN, USA)
   
15:00S4.4Novel treatments - from PCR to patient
K Newbold (London)
   
15:30 16:00  TEA & COFFEE
HALL Q
16:00 18:00  Oral Communications 2: REPRODUCTION AND BONE
QUEEN'S SUITE B
Chairs: A McNeilly (Edinburgh) & E Vasilopoulou (Birmingham)
16:00OC2.1The expression of kisspeptin and kisspeptin receptor is altered in pre-eclampsia
P Williams (Nottingham)
   
16:15OC2.2Contrasting effects of kisspeptin-10 between men and women reveal sexual dimorphism in the hypothalamic regulation of human reproduction
C Jayasena (London)
   
16:30OC2.3Kissorphin, a hexapeptide derivative of kisspeptin, acts via neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no gonadotrophin-releasing hormone releasing activity
N Milton (London)
   
16:45OC2.4ERβ and GPR30 mediate distinct and opposite oestrogenic influences on microglial phagocytosis of apoptotic neuronal cells
S Vohra (London)
   
17:00OC2.5Nutrient regulation of growth factor signalling in human placenta
R Nadif (Manchester)
   
17:15OC2.6Identification of microRNAs involved in regulating growth factor signalling in the first trimester placenta
F Farrokhnia (Manchester)
   
17:30OC2.7Increased cardiovascular events in women with polycystic ovary syndrome: retrospective analysis of a large database
H Mani (Leicester)
   
17:45OC2.8A calcium-sensing receptor (CaSR) variant, Glu250Lys, present in familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemic hypercalciuria (ADHH) probands represents a functionally neutral polymorphism: lessons for CaSR mutational analysis
F Hannan (Oxford)
   
16:00 18:00  Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Muscle is recognised as important endocrine organ and target for the treatment of metabolic syndrome. This symposium will explore the breadth of our new understanding of basic metabolism and investigative clinical data that is currently emerging.
QUEEN'S SUITE A
Chairs: G Lavery (Birmingham) & N Morton (Edinburgh)
16:00S5.1Muscles and their myokines
B Pedersen (Copenhagen, Denmark)
   
16:30S5.2Exercise effects on fat metabolism and insulin sensitivity in human muscle
A Wagenmakers (Birmingham)
   
17:00S5.3Novel signalling mechanisms controlling glycogen homeostasis in muscle
K Sakamoto (Dundee)
   
17:30S5.4Mitochondrial dysfunction and muscle disease
S Rahman (London)
   
16:00 18:00  Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
Two million people in the UK are living with or beyond cancer. Many are at risk of endocrinopathy
SUPPORTED BY CLINICAL ENDOCRINOLOGY, DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S LATE EFFECTS OF CANCER THERAPY SPECIAL INTEREST GROUP
MAIN AUDITORIUM
Chairs: M Druce (London) & A Kennedy (Birmingham)
16:00CM1.1The follow up of cancer survivors
D Greenfield (Sheffield)
   
16:30CM1.2The impact of cancer treatment on pituitary function
A Toogood (Birmingham)
   
17:00CM1.3The impact of cancer treatment on fertility and pregnancy
H Wallace (Edinburgh)
   
17:30CM1.4The late consequences of cancer therapy to the thyroid
G Brabant (Manchester)
   
18:00 18:10  BREAK
18:10 19:10  YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
MAIN AUDITORIUM
Chairs: K Chapman (Edinburgh) & A Grossman (London)
18:10YEP1.1Challenging the dogma: Tissue specific regulation of insulin action
L Gathercole (Birmingham)
   
18:40YEP1.2Quantifying in vivo extra-adrenal cortisol production and dysregulation in human metabolic disease
R Stimson (Edinburgh)
   
19:10 21:00  WELCOME RECEPTION
HALL Q
19:45   YOUNG ENDOCRINOLOGISTS' SOCIAL EVENING
HALL D
20 March 2012
07:00 07:15  BREAKFAST
MAIN AUDITORIUM FOYER & QUEEN'S SUITE FOYER
07:15 08:00  MEET THE EXPERT 1
Therapeutic management of adults with CAH
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Ahmed (Glasgow)
Expert: W Arlt (Birmingham)
07:15MTE1Therapeutic management of adults with CAH
W Arlt (Birmingham)
   
07:15 08:00  MEET THE EXPERT 2
Amiodarone
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: A Weetman (Sheffield)
Expert: M Vanderpump (London)
07:15MTE2Amiodarone
M Vanderpump (London)
   
07:15 08:00  MEET THE EXPERT 3
Preventing and managing long term complications of acromegaly
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chair: R Murray (Leeds)
Expert: K Meeran (London)
07:15MTE3Preventing and managing long term complications of acromegaly
K Meeran (London)
   
08:15 10:15  Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Novel drugs targeting steroid synthesis and metabolism provide new avenues for treating human diseases
QUEEN'S SUITE A
Chairs: W Arlt (Birmingham) & S Alvarez-Madrazo (Glasgow)
08:15S6.1Ageing gracefully - the role of 11beta-HSD1
M Cooper (Birmingham)
   
08:45S6.2Old drugs for new targets - CYP11B2 inhibitors for hypertension
R Bernhardt (Saarbrucken, Germany)
   
09:15S6.3Dual aromatase and steroid sulfatase inhibition in breast cancer
P Foster (Birmingham)
   
09:45S6.4Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone
E Wilson (Chapel Hill, NC, USA)
   
08:15 10:15  Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
QUEEN'S SUITE B
Chairs: A Brooke (Exeter) & N Schoenmakers (Cambridge)
08:15OC3.1Metformin in obese children and adolescents (MOCA) trial
D Kendall (Manchester)
   
08:30OC3.2Post-prandial high fat intake leads to acute exposure to circulating endotoxin in type 2 diabetes mellitus subjects
A Harte (Coventry)
   
08:45OC3.3Risk of diabetes, cancer, large vessel disease and mortality in young women with polycystic ovary syndrome: a retrospective databased analysis
C Morgan (Cardiff)
   
09:00OC3.4Glucose absorption capacity of the mature adipose tissue is increased after Bardet-Biedl syndrome induced ciliary defect in adipocytes' precursors
V Marion (Strasbourg, France)
   
09:15OC3.5Steroidogenic function following B lymphocyte depletion therapy in new onset autoimmune Addison's disease
S Pearce (Newcastle)
   
09:30OC3.6GATA3 polymorphisms are associated with autoimmune Addison's disease
A Mitchell (Newcastle)
   
09:45OC3.7Subclinical hypothyroidism is associated with fatigue and impaired functional status in males in the Whickham 20-year follow up cohort
A Madathil (Newcastle)
   
10:00OC3.8Dietary factors augment the ability of the proto-oncogene PBF to induce goitrogenesis and hyperplasia in vivo
M Read (Birmingham)
   
08:15 10:15  Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S BONE AND MINERAL SPECIAL INTEREST GROUP
MAIN AUDITORIUM
Chairs: S Orme (Leeds) & C Higham (Manchester)
08:15CM2.1Impact of lifestyle choices on skeletal health
N Peel (Sheffield)
   
08:45CM2.2Osteoporosis and metabolic bone disease in adolescence
N Bishop (Sheffield)
   
09:15CM2.3Complications of antiresorptive agents
B Abrahamsen (Copenhagen, Denmark)
   
09:45CM2.4New and emerging therapies for osteoporosis
R Eastell (Sheffield)
   
10:15 10:40  TEA & COFFEE
HALL Q
10:40 11:20  SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
MAIN AUDITORIUM
Chair: J Buckingham (London)
10:40PL1Estrogen receptor insensitivity: physiological and clinical consequences
K Korach (Durham, NC, USA)
   
11:20 12:00  SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
11:20PL2Bone as endocrine organ
G Karsenty (New York, NY, USA)
   
12:00 14:00  LUNCH & POSTERS
HALL Q
14:00 16:00  Oral Communications 4: Steroids
QUEEN'S SUITE A
Chairs: R Bernhardt (Saarbrucken, Germany) & F McManus (Glasgow)
14:00OC4.1Increased 11β-hydroxysteroid dehydrogenase type 1 activity is associated with the adverse expression of glucocorticoid target genes in ageing human skin
A Tiganescu (Birmingham)
   
14:15OC4.2Age-dependent increase in the expression/activity of 11β-HSD1 in key metabolic tissues may underpin the ageing phenotype, notably sarcopenia
S Morgan (Birmingham)
   
14:30OC4.3A hypomorphic H6PD allele is sufficient to rescue the skeletal myopathy but not the lack of 11β-HSd type-1 mediated glucocorticoid regeneration phenotypes of H6PDKO mice
A Zielinska (Birmingham)
   
14:45OC4.4Broad phenotypic spectrum of 17a-hydroxylase deficiency: functional characterisation of 4 novel mutations in the CYP17A1 gene
J Idkowiak (Birmingham)
   
15:00OC4.5A novel repressor mechanism regulating fetal Leydig cell steroidogenesis, pertubation of which results in masculinization disorders
S van den Driesche (Edinburgh)
   
15:15OC4.6Fatty liver in a mouse model of congenital adrenal hyperplasia is driven by peroxisome proliferator-activated receptors
K McInnes (Edinburgh)
   
15:30OC4.7Glucocorticoids increase subcutaneous adipose tissue insulin sensitivity in vivo: a randomised double-blind, placebo controlled, cross over study
J Hazlehurst (Birmingham)
   
15:45OC4.8The role of a novel co-regulator in modifying the transcriptional activities of the glucocorticoid receptor
M Sadeq (Manchester)
   
14:00 16:00  Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
As humans have migrated towards the poles, a number of changes have occurred to our endocrine systems which have allowed us to adapt to our new environment, particularly daily and seasonal changes in light intensity and duration. In this symposium we will explore those endocrine systems most affected by latitudinal light levels and our adaptations to overcome these changes
MAIN AUDITORIUM
Chairs: D Renshaw (London) & A McNeilly (Edinburgh)
14:00S7.1The origins and evolution of lactase persistence
M Thomas (London)
   
14:30S7.2Melatonin, light and sleep in the Antartic
J Arendt (Guildford)
   
15:00S7.3Cortisol and mood - coping with seasons
A Clow (London)
   
15:30S7.4Resurgence of vitamin D deficiency rickets in the UK
Z Mughal (Manchester)
   
14:00 16:00  Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
QUEEN'S SUITE B
Chairs: V Cabrera-Sharp (London) & S Mirczuk (London)
14:00YE1.1Obtaining fellowship funding and networking
K Forbes (Manchester)
   
14:30YE1.2Pathways in clinical academia, fellowships and networking
A Tahrani (Birmingham)
   
15:00YE1.3Career opportunities in the States
I Thompson (Boston, MA, USA)
   
15:30YE1.4Trials and tribulations of the university lecturer
R Fowkes (London)
   
16:00 16:30  TEA & COFFEE
HALL Q
16:30 17:30  Clinical Debate:
THIS HOUSE BELIEVES THAT ALL ADRENAL PATIENTS WITH INCIDENTALOMA WHO FAIL TO SUPPRESS CORTISOL AFTER DEXAMETHASONE SHOULD HAVE AN ADRENALECTOMY
MAIN AUDITORIUM
Chair: S Shalet (Manchester)
For: B Atkinson (Belfast) Against: P Stewart (Birmingham)
16:30 17:15  MEET THE EXPERT 1 - REPEAT
Therapeutic management of adults with CAH
SUPPORTED BY CLINICAL ENDOCRINOLOGY
HALL D
Chair: S Ahmed (Glasgow)
Expert: W Arlt (Birmingham)
16:30MTE1Therapeutic management of adults with CAH
W Arlt (Birmingham)
   
16:30 18:30  Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
QUEEN'S SUITE A
Chairs: J Webster (Sheffield) & V Smith (Birmingham)
16:30OC5.1Human growth is regulated by an ubiquitination pathway including CUL7, OBSL1 and CCDC8
D Hanson (Manchester)
   
16:45OC5.2A network analysis of gene expression through childhood highlights changes related to age and growth
A Stevens (Manchester)
   
17:00OC5.3Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?
C Sze (London)
   
17:15OC5.4Steroid metabolomics in adrenocortical carcinoma reveal mitotane as an inducer of CYP3A4 and an inhibitor of 5alpha-reductase activity with major implications for drug metabolism and hydrocortisone replacement
A Taylor (Birmingham)
   
17:30OC5.5Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas
D Pinato (London)
   
17:45OC5.6SUMOylation genes in pituitary gonadotrophs: wrestling with GnRH signalling
S Mirczuk (London)
   
18:00OC5.7The role of the familialpituitary adenoma gene, AIP, in the proliferative and invasive activity of a malignant pancreatic cell line
J Saleh (London)
   
18:15OC5.8Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment
T Howlett (Leicester)
   
16:30 18:30  Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNAs have emerged in recent years as key regulators in cancer and endocrine disease. They dramatically modify gene expression at the post-transcriptional stage
QUEEN'S SUITE B
Chairs: M Westwood (Manchester) & S Wood (Glasgow)
16:30S8.1MicroRNA: an introduction
M Bushall (Leicester)
   
17:00S8.2MicroRNA regulation of the IGF axis
K Forbes (Manchester)
   
17:30S8.3MicroRNA and the beta-cell
M Poy (Berlin, Germany)
   
18:00S8.4MicroRNA in the diagnosis and therapy of endcorine cancers
P Igaz (Budapest, Hungary)
   
17:15 18:00  MEET THE EXPERT 2 - REPEAT
Amiodarone
SUPPORTED BY CLINICAL ENDOCRINOLOGY
HALL D
Chair: A Weetman (Sheffield)
Expert: M Vanderpump (London)
17:15MTE2Amiodarone
M Vanderpump (London)
   
18:40 19:10  SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
MAIN AUDITORIUM
Chair: P Stewart (Birmingham)
18:40PL3Metabolism to epigenetics: the circadian clock link
P Sassone-Corsi (Irvine, CA, USA)
   
19:40 00:00  CONFERENCE DINNER
ROYAL HALL
21 March 2012
07:00 07:15  BREAKFAST
QUEEN'S SUITE FOYER
07:15 08:00  MEET THE EXPERT 4
Management of persistent TSH elevation in hypothyroid patients
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
QUEEN'S SUITE A
Chair: J Wass (Oxford)
Expert: A Allahabadia (Sheffield)
07:15MTE4Management of persistent TSH elevation in hypothyroid patients
A Allahabadia (Sheffield)
   
07:15 08:00  MEET THE EXPERT 5
The surgical approaches to MEN1 - what the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: S Ball (Newcastle)
Expert: B Harrison (Sheffield)
07:15MTE5The surgical approaches to MEN1 - what the endocrinologist needs to know
B Harrison (Sheffield)
   
08:00 08:10  BREAKFAST
MAIN AUDITORIUM FOYER
08:10 08:55  SOCIETY FOR ENDOCRINOLOGY ANNUAL GENERAL MEETING
MAIN AUDITORIUM
09:00 11:00  Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
It’s not what I eat, it’s what my mother ate. Can maternal lifestyle or nutrition programme life-long metabolic and endocrine problems in their offspring.
QUEEN'S SUITE A
Chairs: A Fowden (Cambridge) & O Brand (Oxford)
09:00S9.1Developmental programming of type 2 diabetes
S Ozanne (Cambridge)
   
09:30S9.2Neuroendocrine origins of obesity
S Bouret (Los Angeles, CA, USA)
   
10:00S9.3The foetus or the placenta? Targets of glucorticoid programming
M Holmes (Edinburgh)
   
10:30S9.4Obesity in pregnancy: implications for the next generation
S Ford (Laramie, WY, USA)
   
09:00 11:00  Symposium 10:
CURRENT CONCEPTS AND MANAGEMENT OF PHAEOCHROMOCYTOMA
SUPPORTED BY THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
MAIN AUDITORIUM
Chairs: J Connell (Dundee) & U Srirangalingam (London)
09:00S10.1Genetics and epidemiology
E Maher (Birmingham)
   
09:30S10.2Molecular mechanisms of phaeochromocytoma and tumorigenesis
P Dahia (San Antonio, TX, USA)
   
10:00S10.3Laboratory assessment and diagnostic imaging
H Timmers (Nijmegen, The Netherlands)
   
10:30S10.4Novel therapies for malignant phaeochromocytomas and paragangliomas
P-F Plouin (Paris, France)
   
09:00 11:00  Nurses' Session 1:
THYROID EYE DISEASE
SUPPORTED BY THE THYROID EYE DISEASE CHARITABLE TRUST
QUEEN'S SUITE B
Chairs: D Wright (Bradford) & N Ellis (Bradford)
09:00N1.1Thyroid Eye Disease - presentation and treatment
R Ajjan (Leeds)
   
10:00N1.2Thyroid Eye Disease
M Morris (Newcastle)
   
10:30N1.3Thyroid Eye Disease
J McLaren (Thyroid Eye Disease Charitable Trust)
   
11:00 11:30  TEA & COFFEE
11:30 12:00  SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
MAIN AUDITORIUM
Chair: M Korbonits (London)
11:30PL4GLP-1 therapy of type 2 diabetes - current status
J Juul-Holst (Copenhagen, Denmark)
   
12:00 12:30  SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
12:00PL5Acromegaly - improving outcomes
M Sheppard (Birmingham)
   
12:30 13:45  LUNCH
HALL Q
13:45 15:45  Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Recent breakthroughs from the genetics of mineralocorticoid hypertension
QUEEN'S SUITE A
Chairs: E Davies (Glasgow) & E Nogueira (Birmingham)
13:45S11.1A difficult TASK: murine models of mineralocorticoid excess
R Warth (Regensburg, Germany)
   
14:15S11.2Human potassium channel mutations and mineralocorticoid hypertension
M Zennaro (Paris, France)
   
14:45S11.3Long term consequences of primary hyperaldosteronism
M Reincke (Munich, Germany)
   
15:15S11.4Therapeutic options for mineralocorticoid hypertension
J Connell (Dundee)
   
13:45 15:45  Symposium 12: MEDULLARY THYROID CANCER
Emerging knowledge of the molecular mechanisms in medullary carcinoma of the thyroid is improving our understanding of this condition, which is now impacting on therapy
MAIN AUDITORIUM
Chairs: D Bassett (London) & V Smith (Birmingham)
13:45S12.1Molecular pathogenesis of MTC
M Santoro (Naples, Italy)
   
14:15S12.2RAS mutations in sporadic MTC
V Leite (Lisbon, Portugal)
   
14:45S12.3The diagnosis and management of MTC
T Kurzawinski (London)
   
15:15S12.4Novel targeted therapies for MTC
M Schlumberger (Paris, France)
   
13:45 15:45  Nurses' Session 2:
ADDISON'S/PHAEOCHROMOCYTOMAS/CONN'S SYNDROME
QUEEN'S SUITE B
Chairs: S Gorick (Norwich) & V Kieffer (Leicester)
13:45N2.1Conn's and phaeochromocytoma
S Myint (Norwich)
   
14:15N2.2Nursing case study on phaeochromocytoma
P Yeoh (London)
   
14:30N2.3Introduction to Addison's
T Howlett (Leicester)
   
15:00N2.4Day-to-day practice on management of steroid replacement
V Thornton-Jones (Oxford)
   
15:15N2.5Living with Addison's
H Dawson-Smith (Addison's Disease Self-Help Group)
   
13:45 14:30  MEET THE EXPERT 8
Optogenetics: controlling cells with light
HALL D
Chair: R Andrew (Edinburgh)
Expert: R Allemann (Cardiff)
13:45MTE8Optogenetics: controlling cells with light
R Allemann (Cardiff)
   
14:45 15:30  MEET THE EXPERT 9
All you need to know about CHIP-sequencing
HALL D
Chair: C McCabe (Birmingham)
Expert: J Carroll (Cambridge)
14:45MTE9All you need to know about CHIP-sequencing
J Carroll (Cambridge)
   
15:45 16:15  TEA & COFFEE
HALL Q
16:15 16:45  AWARDS CEREMONY
MAIN AUDITORIUM
Chair: J Buckingham (London)
17:15 17:45  SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
MAIN AUDITORIUM
Chair: J Buckingham (London)
17:15PL7Genetic, molecular and physiological mechanisms involved in human obesity
S Farooqi (Cambridge)
   
18:00 18:45  BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
16:45PL6The thyroid - too much and too little across the ages
J Franklyn (Birmingham)
   
18:00 19:30  Otsuka satellite symposium
Chair: P Bouloux (London)
18:00OS1Hyponatraemia in neurosurgical patients: insights and implications
   
18:45OS2Accelerating post-aneurysm recovery by correcting hypotraemia
   
18:00 19:30  How do we balance a 21st century medicine with a 21st century economy?
22 March 2012
07:00 07:15  BREAKFAST
QUEEN'S SUITE FOYER
07:30 08:15  MEET THE EXPERT 6
Prioritising therapy in neuroendocrine tumours
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Aylwin (London)
Expert: C Toumpanakis (London)
07:30MTE6Prioritising therapy in neuroendocrine tumours
C Toumpanakis (London)
   
07:30 08:15  MEET THE EXPERT 7
Regulating periods and optimising fertility in PCOS
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: H Randeva (Warwick)
Expert: C Duncan (Edinburgh)
07:30MTE7Regulating periods and optimising fertility in PCOS
C Duncan (Edinburgh)
   
08:30 09:00  CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
Developing growth hormone agonists and antagonists for the clinic
SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
MAIN AUDITORIUM
Chair: J Bevan (Aberdeen)
08:30PL8Developing growth hormone agonists and antagonists for the clinic
R Ross (Sheffield)
   
09:00 09:30  CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
Long-term outcome and quality of life in patients with disorders of sex development
SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
MAIN AUDITORIUM
Chair: J Connell (Dundee)
09:00PL9Long-term outcome and quality of life in patients with disorders of sex development
B Mendoca (Sao Paulo, Brazil)
   
09:30 10:00  Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
MAIN AUDITORIUM
09:30FO1.1Opportunities in translational research - the NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
R Thakker (London)
   
09:45FO1.2NIHR research networks: an update
J Wilding (Liverpool)
   
10:00 10:30  TEA & COFFEE
HALL Q
10:30 13:00  SENIOR ENDOCRINOLOGISTS' SESSION
HALL D
10:30SE1.1Seeing the light
B Cooke (Harpenden)
   
10:55SE1.2It's time to identify the hormone that maintains bodty fat content
G Hervey (Leeds)
   
11:20SE1.3UK stance on adult GH replacment maintains our isolation from Europe
S Shalet (Manchester)
   
11:45SE1.4Assisted conception and developing low cost version for the developing world
I Cooke (Sheffield)
   
12:10SE1.5Tales from an arthritic endocrinologist - why does the endocrine dog not bark in the cytokine night?
C Edwards (London)
   
12:35SE1.6Psychopathology of false conviction
D Anderson (Montecastello di Vibio, Italy)
   
10:30 12:30  Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
What the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chairs: W Dhillo (London) & J George (Edinburgh)
10:30CM3.1Novel mutations causing infertility
N Pitteloud (Lausanne, Switzerland)
   
11:00CM3.2Semen analysis: what does it mean and can we improve it?
C Barratt (Dundee)
   
11:30CM3.3How can we predict ovarian reserve and how useful is this?
F Broekmans (Utrecht, The Netherlands)
   
12:30CM3.4The endocrine basis of what we do in the IVF clinic
G Trew (London)
   
10:30 12:30  Clinical Management Workshop 4: HOW DO I APPROACH...
Real world approaches to clinical dilemmas
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chairs: J Bevan (Aberdeen) & A Paisley (Manchester)
10:30CM4.1Drug-induced hyperprolactinaemia
T Kearney (Salford)
   
10:50CM4.2Endocrine assessment in HIV/AIDS
A Wren (London)
   
11:10CM4.3Neuroendocrine assessment in morbid obesity
J Wilding (Liverpool)
   
11:30CM4.4Endocrine evaluation in a patient with coeliac disease
S Pearce (Newcastle)
   
11:50CM4.5Hypogonadism in a man with cancer of the prostate
H Jones (Sheffield)
   
12:10CM4.6Endocrine evaluation in a patient with iron overload
J Kirk (Birmingham)
   
12:30 13:15  MEET THE EXPERT 5 - REPEAT
The surgical approaches to MEN1 - what the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chair: S Ball (Newcastle)
Expert: B Harrison (Sheffield)
12:30MTE5The surgical approaches to MEN1 - what the endocrinologist needs to know
B Harrison (Sheffield)
   
12:30 13:15  MEET THE EXPERT 4 - REPEAT
Management of persistent TSH elevation in hypothyroid patients
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
QUEEN'S SUITE B
Chair: J Wass (Oxford)
Expert: A Allahabadia (Sheffield)
12:30MTE4Management of persistent TSH elevation in hypothyroid patients
A Allahabadia (Sheffield)
   
12:30 13:15  MEET THE EXPERT 3 - REPEAT
Preventing and managing long term complications of acromegaly
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: R Murray (Leeds)
Expert: K Meeran (London)
12:30MTE3Preventing and managing long term complications of acromegaly
K Meeran (London)
   
13:15 14:00  MEET THE EXPERT 7 - REPEAT
Regulating periods and optimising fertility in PCOS
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: H Randeva (Warwick)
Expert: C Duncan (Edinburgh)
13:15MTE7Regulating periods and optimising fertility in PCOS
C Duncan (Edinburgh)
   
13:15 14:00  MEET THE EXPERT 6 - REPEAT
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Aylwin (London)
Expert: C Toumpanakis (London)
13:15MTE6Prioritising therapy in neuroendocrine tumours
C Toumpanakis (London)